[{"orgOrder":0,"company":"Atom Therapeutics","sponsor":"China Medical System Holdings","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Lingdolinurad","moa":"","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Atom Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"","sponsorNew":"Atom Therapeutics \/ China Medical System Holdings","highestDevelopmentStatusID":"9","companyTruncated":"Atom Therapeutics \/ China Medical System Holdings"}]

Find Clinical Drug Pipeline Developments & Deals for Lingdolinurad

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          RNA Therapeutics
                          Not Confirmed
                          RNA Therapeutics
                          Not Confirmed

                          Details : The collaboration aims for the commercialization of ABP-671 (lingdolinurad), a novel oral small molecule URAT1 inhibitor for the treatment of chronic gout and hyperuricemia.

                          Product Name : Undisclosed

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          December 03, 2024

                          Lead Product(s) : Lingdolinurad

                          Therapeutic Area : Rheumatology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : China Medical System Holdings

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank